BC Week In Review | Dec 24, 2012
Company News

DUSA, Sun Pharmaceutical deal

Sun completed its tender offer to acquire DUSA for $8 per share in cash, or about $230 million. Sun said it would complete the acquisition via a short-form merger (see BioCentury, Nov. 12). DUSA Pharmaceuticals...
BC Week In Review | Nov 12, 2012
Company News

DUSA, Sun Pharmaceutical deal

Sun will acquire DUSA for $8 per share in cash, or about $230 million. The price is a 38% premium to DUSA's close of $5.78 on Nov. 7, before the deal was announced. The boards...
BioCentury | Nov 12, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Corcept Therapeutics Inc. (NASDAQ:CORT) fell $0.30 (16%) to $1.60 on Wednesday after FDA's Endocrinologic and Metabolic Drugs Advisory committee voted 10-0 that efficacy and safety data for pasireotide from competitor Novartis AG (NYSE:NVS;...
BC Extra | Nov 9, 2012
Company News

Sun to acquire DUSA

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) will acquire dermatology company DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) for $8 per share in cash, or about $230 million. The price is a 38% premium to DUSA's close of $5.78...
BC Week In Review | Sep 17, 2012
Clinical News

Levulan PDT aminolevulinic acid: Phase II data

A double-blind, U.S. Phase II trial in 70 patients with minimally to moderately thick AK on the upper extremities showed that broad area application of Levulan Kerastick for 3 hours with or without occlusion followed...
BioCentury | Sep 17, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Cornerstone Therapeutics Inc. (NASDAQ:CRTX) fell $1.37 (21%) to $5.10 on Thursday after FDA's Cardiovascular and Renal Drugs Advisory Committee recommended against approval of lixivaptan to treat hypervolemic hyponatremia associated with chronic heart failure...
BC Extra | Sep 14, 2012
Clinical News

DUSA up on actinic keratosis data

DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.37 to $5.75 on Thursday after Levulan Kerastick followed by DUSA's Blue Light Photodynamic Therapy Illuminator (BLU-U) met the primary endpoint in a Phase II trial in 70 patients with...
BC Week In Review | Jul 26, 2010
Company News

Nitric BioTherapeutics board of directors update

Nitric BioTherapeutics Inc. , Bristol, Pa.   Business: Infectious, Dermatology   Appointed: Al Altomari as executive chairman, a director at Auxilium Pharmaceuticals Inc. , DUSA Pharmaceuticals Inc. and Signum Biosciences Inc.  ...
BC Week In Review | Nov 16, 2009
Clinical News

Levulan PDT aminolevulinic acid: Pilot trial data

Data from a prospective, open-label pilot trial in 12 patients who had received a kidney and/or heart transplant over the past 5-30 years showed that topical Levulan PDT applied prior to DUSA's Blue Light Photodynamic...
BC Week In Review | Aug 17, 2009
Clinical News

Levulan PDT aminolevulinic acid regulatory update

DUSA said FDA rejected its application for Orphan Drug designation for Levulan PDT to prevent cancer occurrence in high-risk, chronically immunosuppressed solid organ transplant recipients. The company said, FDA determined the prevalence of the condition...
Items per page:
1 - 10 of 118
BC Week In Review | Dec 24, 2012
Company News

DUSA, Sun Pharmaceutical deal

Sun completed its tender offer to acquire DUSA for $8 per share in cash, or about $230 million. Sun said it would complete the acquisition via a short-form merger (see BioCentury, Nov. 12). DUSA Pharmaceuticals...
BC Week In Review | Nov 12, 2012
Company News

DUSA, Sun Pharmaceutical deal

Sun will acquire DUSA for $8 per share in cash, or about $230 million. The price is a 38% premium to DUSA's close of $5.78 on Nov. 7, before the deal was announced. The boards...
BioCentury | Nov 12, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Corcept Therapeutics Inc. (NASDAQ:CORT) fell $0.30 (16%) to $1.60 on Wednesday after FDA's Endocrinologic and Metabolic Drugs Advisory committee voted 10-0 that efficacy and safety data for pasireotide from competitor Novartis AG (NYSE:NVS;...
BC Extra | Nov 9, 2012
Company News

Sun to acquire DUSA

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) will acquire dermatology company DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) for $8 per share in cash, or about $230 million. The price is a 38% premium to DUSA's close of $5.78...
BC Week In Review | Sep 17, 2012
Clinical News

Levulan PDT aminolevulinic acid: Phase II data

A double-blind, U.S. Phase II trial in 70 patients with minimally to moderately thick AK on the upper extremities showed that broad area application of Levulan Kerastick for 3 hours with or without occlusion followed...
BioCentury | Sep 17, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Cornerstone Therapeutics Inc. (NASDAQ:CRTX) fell $1.37 (21%) to $5.10 on Thursday after FDA's Cardiovascular and Renal Drugs Advisory Committee recommended against approval of lixivaptan to treat hypervolemic hyponatremia associated with chronic heart failure...
BC Extra | Sep 14, 2012
Clinical News

DUSA up on actinic keratosis data

DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.37 to $5.75 on Thursday after Levulan Kerastick followed by DUSA's Blue Light Photodynamic Therapy Illuminator (BLU-U) met the primary endpoint in a Phase II trial in 70 patients with...
BC Week In Review | Jul 26, 2010
Company News

Nitric BioTherapeutics board of directors update

Nitric BioTherapeutics Inc. , Bristol, Pa.   Business: Infectious, Dermatology   Appointed: Al Altomari as executive chairman, a director at Auxilium Pharmaceuticals Inc. , DUSA Pharmaceuticals Inc. and Signum Biosciences Inc.  ...
BC Week In Review | Nov 16, 2009
Clinical News

Levulan PDT aminolevulinic acid: Pilot trial data

Data from a prospective, open-label pilot trial in 12 patients who had received a kidney and/or heart transplant over the past 5-30 years showed that topical Levulan PDT applied prior to DUSA's Blue Light Photodynamic...
BC Week In Review | Aug 17, 2009
Clinical News

Levulan PDT aminolevulinic acid regulatory update

DUSA said FDA rejected its application for Orphan Drug designation for Levulan PDT to prevent cancer occurrence in high-risk, chronically immunosuppressed solid organ transplant recipients. The company said, FDA determined the prevalence of the condition...
Items per page:
1 - 10 of 118